Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. by Jallow, Sabelle et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
International Health and Tropical Medicine Articles Department of International Health and TropicalMedicine
1-7-2009
Virological response to highly active antiretroviral
therapy in patients infected with human
immunodeficiency virus type 2 (HIV-2) and in
patients dually infected with HIV-1 and HIV-2 in
the Gambia and emergence of drug-resistant
variants.
Sabelle Jallow
Medical Research Council Laboratories, Banjul
Abraham Alabi
Medical Research Council Laboratories, Banjul
Ramu Sarge-Njie
Medical Research Council Laboratories, Banjul
Kevin Peterson
Medical Research Council Laboratories, Banjul
Hilton Whittle
Medical Research Council Laboratories, Banjul
This Article is brought to you for free and open access by the Department
of International Health and Tropical Medicine at e-publications@RCSI. It
has been accepted for inclusion in International Health and Tropical
Medicine Articles by an authorized administrator of e-publications@RCSI.
For more information, please contact epubs@rcsi.ie.
Citation
Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, Jaye A, Cotten M, Vanham G, McConkey SJ, Rowland-Jones S,
Janssens W. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2
(HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. Journal of
Clinical Microbiology. 2009;47(7):2200-8
See next page for additional authors
Authors
Sabelle Jallow, Abraham Alabi, Ramu Sarge-Njie, Kevin Peterson, Hilton Whittle, Tumani Corrah, Assan Jaye,
Matthew Cotten, Guido Vanham, Samuel McConkey, Sarah Rowland-Jones, and Wouter Janssens
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/ihtmart/8
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/ihtmart/8
JOURNAL OF CLINICAL MICROBIOLOGY, July 2009, p. 2200–2208 Vol. 47, No. 7
0095-1137/09/$08.000 doi:10.1128/JCM.01654-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Virological Response to Highly Active Antiretroviral Therapy in Patients
Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in
Patients Dually Infected with HIV-1 and HIV-2 in The Gambia and
Emergence of Drug-Resistant Variants
Sabelle Jallow,1,2* Abraham Alabi,1 Ramu Sarge-Njie,1 Kevin Peterson,1 Hilton Whittle,1
Tumani Corrah,1 Assan Jaye,1 Matthew Cotten,1 Guido Vanham,2,3 Samuel J. McConkey,1†
Sarah Rowland-Jones,1,4 and Wouter Janssens2
Medical Research Council Laboratories (MRC), Banjul, The Gambia1; Department of Microbiology, Institute of Tropical Medicine,2 and
Department of Biomedical Sciences, University of Antwerp,3 Antwerp, Belgium; and Weatherall Institute of Molecular Medicine,
Medical Research Council, Human Immunology Unit, John Radcliffe Hospital, Oxford, United Kingdom4
Received 26 August 2008/Returned for modification 17 January 2009/Accepted 7 April 2009
Drug design, antiretroviral therapy (ART), and drug resistance studies have focused almost exclusively
on human immunodeficiency virus type 1 (HIV-1), resulting in limited information for patients infected
with HIV-2 and for those dually infected with HIV-1 and HIV-2. In this study, 20 patients, 12 infected with
HIV-2 and 8 dually infected with HIV-1 and HIV-2, all treated with zidovudine (ZDV), lamivudine (3TC),
and lopinavir-ritonavir (LPV/r), were followed up longitudinally for about 3 years. For 19/20 patients, viral
loads were reduced to undetectable levels; the patient whose viral load remained detectable reported
adverse effects associated with LPV/r that had caused him to stop taking all the drugs. HIV-2 strains
containing mutations in both the protease and the reverse transcriptase gene that may confer drug
resistance were observed in two patients with viral rebound, as early as 130 days (4.3 months) after the
initiation of therapy. We conclude that the combination of ZDV, 3TC, and LPV/r is able to provide efficient
and durable suppression of HIV-1 and HIV-2 for as long as 3 years in HIV-2-infected and dually infected
patients. However, the emergence of HIV-1 and HIV-2 strains containing drug-resistant mutations can
compromise the efficacy of this highly active ART.
Human immunodeficiency virus type 2 (HIV-2) is the sec-
ond human immunodeficiency virus known to cause AIDS (8).
However, this retrovirus, although very similar to HIV-1, usu-
ally presents an attenuated HIV infection with lower plasma
viral loads, a slower decline in the number of CD4 T cells, a
longer asymptomatic phase, and much lower transmission rates
(2–5, 20, 29, 34, 40, 47, 51).
Highly active antiretroviral therapy (HAART) has changed
the face of the AIDS epidemic from a death sentence to a
treatable, chronic infectious disease (46) and has had a dra-
matic effect on mortality, slowing down disease progression
and increasing the quality of life for infected individuals with
access to treatment (16, 17, 44). However, the high mutation
rate of HIV and incomplete viral suppression due to subopti-
mal therapy inevitably result in the emergence of drug-resis-
tant viruses. Suboptimal therapy is associated with low levels of
drugs in the blood due either to lack of adherence to toxic and
complex regimens or to problems with drug absorption or
metabolism (33, 46). The development of drug resistance has
posed a major obstacle to the effective treatment of HIV,
limiting both the magnitude and the duration of the response
to treatment as well as reducing the number of active antiret-
roviral (ARV) drugs available for HAART (33).
Drug development, susceptibility tests, and drug resistance
studies have focused almost exclusively on HIV-1; limited work
has been done on HIV-2. This is due mainly to the lower
prevalence of HIV-2 than of HIV-1 and the restriction of the
HIV-2 epidemic mainly to West Africa, where access to treat-
ment has been limited. The drugs that are currently approved
were designed for HIV-1 subtype B, but due to the highly
conserved nature of the critical HIV-1 and HIV-2 enzymes
protease and reverse transcriptase (RT), especially around the
active sites, it was assumed that these drugs would be active
against both types of HIV infections. The nonnucleoside RT
inhibitors (NNRTIs), however, target allosteric sites of the RT
enzyme, and it was later discovered that HIV-1 group O strains
and HIV-2 are naturally resistant to these drugs (14, 22, 42,
48). In addition, HIV-2 has been found to be naturally resistant
to the entry inhibitor T-20, and it may have reduced suscepti-
bility to some protease inhibitors (PIs) (19, 45, 50). Therefore,
drugs used for the treatment of HIV-2 should be carefully
selected to allow optimal and durable viral suppression. Dual
infection with HIV-1 and HIV-2 occurs mainly in West Africa,
where the two viruses cocirculate. Several papers have indi-
cated that dually infected patients have a disease course similar
to that of patients infected with HIV-1 alone (21, 52). The
presence of HIV-2 in individuals dually infected with HIV-1
and HIV-2 complicates the treatment of these patients (53).
Therefore, the optimal regimen for the treatment of dually
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infected patients should include drugs with simultaneous ac-
tivity against both HIV-1 and HIV-2.
In the developed world, as well as in a few countries in
Africa, a few HIV-2-infected individuals have been treated
with ARV drugs and protocols developed for HIV-1 (1, 6,
9–12, 23, 49). However, the increasing accessibility of these
drugs in Africa means that a substantial number of HIV-2-
infected individuals will be treated, making the study of HIV-2
response to HAART and the development of resistance to
ARV drugs a priority.
We have monitored the response to treatment, and the
emergence of HIV-1 and HIV-2 strains containing potential
drug-resistant mutations, for patients treated with a combina-
tion of two nucleoside RT inhibitors (NRTIs), zidovudine
(ZDV) and lamivudine (3TC), plus a PI, lopinavir-ritonavir
(LPV/r), for as long as 3 years. The presence of HIV strains
containing drug-resistant mutations was analyzed for patients
with viral rebound.
MATERIALS AND METHODS
Study subjects. The Genitourinary Medicine clinic at the Medical Research
Council Laboratories in The Gambia follows a cohort of HIV-2 patients, who are
routinely monitored for CD4 T-cell counts, plasma viral loads, and clinical signs
and symptoms. ARVs became available in The Gambia in 2004, and patients
meeting the criterion of a CD4 T-cell count of 350 cells/ml are now treated
according to the national guidelines. HIV-2-infected patients and patients dually
infected with HIV-1 and HIV-2 are put on a fixed regimen of ZDV, 3TC, and
LPV/r as the first-line regimen. Study subject details are shown in Table 1.
The Joint Gambian government–Medical Research Council Ethics Committee
approved this study.
CD4 T-cell count and viral load. CD4 T-cell measurements were carried out
using flow cytometry (FACSCalibur; Becton Dickinson) (35, 36). The FACS-
Calibur determines both the absolute CD4 cell count (in cells per microliter) and
the CD4 percentage (CD4 T cells as a proportion of total lymphocytes). The
CD4 percentage rather than the absolute CD4 cell count was used to monitor
immunological response, because the former is more stable than the latter, which
is influenced by a number of factors, such as time of day and other concurrent
infections (18, 25). The viral load, expressed as the number of HIV-2 RNA
copies per milliliter of plasma, was quantified using an in-house viral load assay
(4), which has a limit of detection of 100 RNA copies/ml of plasma. This assay
is a quantitative reverse transcription-PCR of the long terminal repeat sequence
of HIV-2, in which the test samples are quantified by comparison with a standard
curve. Test and control PCR products are detected and quantified in an enzyme-
linked oligonucleotide assay (4). This assay was modified to include an internal
molecular control for extraction and amplification efficiency (30).
Nucleic acid extraction, PCR amplification, and sequence analysis. HIV-2
RNA was extracted from 140 l of EDTA-plasma using the QIAamp viral RNA
kit (Qiagen, Venlo, The Netherlands) and was eluted into 50 l nuclease-free
water. The entire HIV-2 protease and RT were amplified using a single-tube
reverse transcription-PCR method (Titan one-tube RT-PCR; Roche Applied
Science, Lewes, United Kingdom) starting from 3 l of RNA, followed by a
nested PCR with Expand High-Fidelity DNA polymerase and 0.5 to 1 l of the
first-round product as previously described (24). Purified PCR products were
directly sequenced on both strands and were analyzed with DNAStar software
(Lasergene; DNAStar, Madison, WI) (24). Sequencing was performed only when
there was detectable viral load during treatment. For one dually infected patient,
HIV-1 became detectable while HIV-2 remained undetectable; therefore, geno-
typing was done for only HIV-1. The inner primers SJH11A (forward; 5-AAA
AGGGCTGTTGGAAATGTGG-3; positions 2018 to 2139) and SJH12A (re-
verse; 5-CCTAATGCATACTGTGAGTCTG-3; positions 4060 to 4039) and
the outer primers SJH13A (forward; 5-GAGAGACAGGCTAATTTTTTA
GGG; positions 2071 to 2094) and SJH14 (reverse; 5-CCTATTAGCTGCCCC
ATCTACATA-3; positions 3893 to 3870) were used to amplify the entire HIV-1
protease and RT. These primer positions refer to HIV-1 HXB2 (GenBank
accession no. K03455). The PCR conditions used for HIV-2 were also used for
HIV-1 except for the annealing temperatures: 56°C was used for the first round,
and 57°C was used for the nested PCR. Three sequencing primers were used to
generate the HIV-1 protease and RT: SHJ13A, SJH14, and SJH15 (forward;
5-GATGTGGGGGAYGCATATTTTTCAG-3; positions 2877 to 2901). The
viral subtype was determined using an online NCBI program (http://www.ncbi
.nih.gov/projects/genotyping/). All HIV-2 strains belonged to subtype A, and the
TABLE 1. Epidemiological, immunological, and virological data of the patients
Patient
no. Reference no. Sex
a Age (yr) HIVtype(s)
Dateb on which ART was: CD4 cellsc VL
c,d (RNA copies/ml
of plasma)
Approved Started % of totallymphocytes
Abse count
(cells/l) HIV-1 HIV-2
1 20041287 M 44 2 3/5/2005 20/5/2005 10 300 315,118
2 20020797 M 54 2 31/5/2005 13/6/2005 5 90 108,650
3 19921115 M 42 2 19/4/2005 5/5/2005 16 180
4 20047429 F 30 2 28/6/2005 22/7/2005 4 130 50,950
5 20053368 M 48 2 16/8/2005 17/8/2005 10 130
6 2003A182 F 43 2 16/8/2005 1/9/2005 5 70 38,645
7 20051154 F 31 2 25/10/2005 17/11/2005 12 180 54,324
8 20052184 M 31 2 25/10/2005 17/11/2005 7 50 120,695
9 20054262 F 46 2 15/11/2005 28/11/2005 8 230 311,055
10 2001A731 F 50 2 15/11/2005 28/11/2005 16 130 3,162
11 20009737 F 31 2 30/11/2004 10/3/2005 4 10 484,047
12 19934174 F 37 2 6/9/2005 19/12/2005 19 210 5,656
13 19813502 F 46 1 and 2 25/1/2005 14/3/2005 11 220 111,867 144,691
14 19927800 F 40 1 and 2 7/12/2004 25/1/2005 7 40 380,315 167
15 19972375 F 28 1 and 2 19/4/2005 5/5/2005 5 160 78,487 5,735
16 20018919 M 49 1 and 2 1/3/2005 4/4/2005 3 40 10,570 41,506
17 20034661 F 38 1 and 2 28/6/2005 22/7/2005 4 210 1,000,000 7,941
18 19965521 F 36 1 and 2 15/11/2005 28/11/2005 12 300 42,462 100
19 20056249 M 30 1 and 2 7/2/2006 2/3/2006 7 60 951,770 100
20 19936825 F 51 1 and 2 16/8/2005 2/3/2006 14 180 1,000,000 37,334
a M, male; F, female.
b Given as day/month/year.
c At the start of therapy.
d VL, viral load.
e Abs, absolute.
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HIV-1 strain in the dually infected patients belonged to the CRF-02_AG sub-
type.
Nucleotide sequence accession numbers. The sequences generated were
assigned EMBL accession numbers AM408175 to AM408184 and FM877562
to FM877574.
RESULTS
The response to therapy for each patient was computed with
respect to the reduction in the viral load during the first few
months of therapy. Among the HIV-2-infected patients, viral
loads were initially reduced to undetectable levels (i.e., 100
copies/ml, the limit of detection) in all but one patient (patient
1), accompanied by an increase in the CD4 T-cell count over
pretherapy levels. The viral load in patient 1 was reduced by 2
log units during the first 2 weeks of therapy but rapidly re-
bounded to pretreatment levels. For seven patients (patients 3,
4, 5, 6, 8, 10, and 12), the viral load is still undetectable after 3
to 28 months on therapy. However, for patient 12, the viral
load dropped slowly and became undetectable only after 5
months. For the rest of the patients (patients 2, 7, 9, and 11),
the viral load was undetectable for 3 to 15 months, but viral
rebound was observed afterwards (Fig. 1). In patients 2 and 11,
the viral load rebounded and returned to undetectable levels
several times, indicating possible problems with adherence.
Among the dually infected patients (patients 13 to 20) (Ta-
ble 1), a very good virological response to therapy was ob-
served for both HIV-1 and HIV-2, as shown by the decline of
both HIV-1 and HIV-2 loads to undetectable levels (Fig. 2). In
seven out of eight patients, viral loads are still undetectable
after 18 to 36 months on therapy. For patient 19, the HIV-1
load increased by 2 log units while the HIV-2 load remained
undetectable.
The reduction of the viral load to undetectable levels was
accompanied by an increase in the percentage of CD4 T cells
for all patients taking this treatment.
The proteases of HIV-1 and HIV-2 have an amino acid
sequence similarity of about 50% (55). Analysis of the HIV-2
protease gene from pretherapy samples showed the presence
of several mutations that are associated with drug resistance
when found in HIV-1. Nine minor HIV-1 mutations, L10V,
G16E, K20R, L33V, M36I, I62V, A71V, G73A, and I93L, and
three major mutations, V32I, M46I, and I47V, were present
FIG. 1. Virological and immunological responses of HIV-2-infected patients treated with ZDV, 3TC, and LPV/r. Graphs depict the changes
in log HIV-2 RNA copies per milliliter of plasma (blue lines) and in the percentages of CD4 T cells (pink lines) over time. The limit of detection
of the viral load (VL) assay is log 2 or 100 copies/ml.
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naturally in all the HIV-2 samples sequenced (Table 2). Also,
polymorphisms were found at positions L76V (M in HIV-2)
and V82A/T/F (I in HIV-2), which are known to harbor major
HIV-1 PI mutations, and at positions of minor mutations,
E34Q (A in HIV-2), D60E (K in HIV-2), and L63P (E in
HIV-2) (10, 11, 49).
The RTs of HIV-1 and HIV-2 have a higher sequence ho-
mology (60%) than the proteases of these viruses (54). As
expected, analysis of the HIV-2 RT gene from pretherapy
samples revealed only a few mutations associated with HIV-1
drug resistance. Two RT mutations—V75I, associated with
multi-NRTI resistance in HIV-1, and K219Q/E, associated
with ZDV resistance in HIV-1—were found to occur naturally
in all HIV-2 samples (Table 3). Polymorphisms were also
found at positions T69D (N in HIV-2), L210W (N in HIV-2),
T215Y/F (S in HIV-2), and G333D/E (Q in HIV-2), known to
harbor HIV-1 RT mutations (Table 3).
Sequence analysis for the presence of drug resistance muta-
tions was performed for 10 patients (9 infected with HIV-2 and
1 dually infected) with detectable viral loads despite therapy.
The protease and RT regions of the sequences were aligned
and analyzed for drug resistance mutations. The alignment of
the patient samples for different time points, before and after
therapy, shows mutations that may have arisen as a result of
drug pressure (Tables 2 and 3). A major HIV-2 PI mutation,
V47A (38), and a primary HIV-1 NRTI mutation, M184V/I,
were observed in patients 2 and 11. Patient 2 had the M184I
mutation after 4 months on ART and the V47A and M184V
mutations after 8.5 months on ZDV, 3TC, and LPV/r (Tables
2 and 3). In addition, the F53V mutation, at a position known
FIG. 2. Virological and immunological responses of patients dually infected with HIV-1 and HIV-2 and treated with ZDV, 3TC, and
LPV/r. Graphs depict changes in log HIV-2 RNA copies per milliliter of plasma (blue lines), in log HIV-1 RNA copies per milliliter of
plasma (purple lines), and in the percentage of CD4 T cells (pink lines) over time. The limit of detection of the viral load (VL) assay is
log2, or 100 copies/ml.
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to harbor PI resistance in HIV-1 (F53Y/L), emerged due to
drug pressure in patient 2 (27). Patient 11 had two PI muta-
tions, V33I and V47A, and the 3TC mutation M184V at the
time of genotyping.
In addition to the known HIV-1 mutations, several other
mutations not previously detected in HIV-1 were observed. In
the protease sequences, the K45N (patient 1), H14R, and
M95I (patient 11) mutations seemed to emerge as a result of
LPV/r pressure, and in the RT sequences, the L260P (patient
1) and V371I (patient 2) mutations seemed to emerge as a
result of ZDV and/or 3TC pressure.
DISCUSSION
Currently approved ARV drugs were designed and opti-
mized for the treatment of HIV-1 subtype B infections. These
drugs were expected to have similar efficacy for HIV-2 patients
as for HIV-1 patients, due to the high structural and enzymatic
function similarities between the protease and RT genes and
proteins of these two viruses (42). However, it was discovered
that HIV-2 is naturally resistant to the NNRTIs and the entry
inhibitor T-20 and that it may have reduced susceptibility to
some PIs (42, 49). These resistance properties restrict the
treatment of HIV-2-infected and dually infected patients with
HAART by limiting the drugs available for the second and
subsequent regimens. The use of a potent and effective first-
line regimen to which HIV-1 is sufficiently sensitive can result
in full viral suppression for more than 7 years (13). Our study
reports durable and efficient suppression of both HIV-1 and
HIV-2 in 19/20 treated patients. Patient 1, whose viral load
remained detectable, had stopped using this treatment due to
adverse effects. Even though previous studies have reported
that various HAART regimens suppress HIV-2 replication by
only 0.4 to 2 log units and usually fail to achieve undetectable
viral loads (1, 41), viral suppression to undetectable levels was
achieved for all patients taking the drugs and was maintained
for as long as 3 years (range, 3 to 36 months). The reduction in
the viral load was accompanied by a general increase in the
percentage of CD4 cells over pretherapy levels, indicating that
these patients were benefiting immunologically from this treat-
ment.
These findings indicate that the combination of ZDV, 3TC,
and LPV/r is effective at achieving efficient and durable viral
suppression in HIV-2-infected and dually infected patients.
The responses to therapy indicate that dually infected pa-
tients seem to do better than singly HIV-2 infected patients.
TABLE 3. Drug resistance mutations emerging as a result of NRTI exposure
Samplea Accessionno.
Amino acidb associated with mutation common in HIV-1 patients exposed to NRTIs
M41L K65R D67N T69D K70R L74V V75I F77L Y115F F116Y Q151M/L M184V L210W T215Y/F K219Q/E G333D/E
WT HIV-1 K03455 M K D T K L V F Y F Q M L T K G
Patient 19
0 FM877573 M K D T K L V F Y F Q M L T K G
559 FM877574 M K D T K L V F Y F Q M L T K G
WT HIV-2 M15390 M K D N K L I F Y F Q M N S E Q
Patient 1
0 AM408175 M K D N K L I F Y F Q M N S E Q
55 AM408176 M K D N K L I F Y F Q M N S E Q
Patient 2
0 AM408177 M K D N K L I F Y F Q M N S E Q
130 AM408178 M K D N K L I F Y F Q I N S E Q
255 AM408179 M K D N K L I F Y F Q V N S E Q
310 FM877562 M K D N K L I F Y F Q V N S E Q
395 FM877563 M K D N K L I F Y F Q V N S E Q
511 FM877564 M K D N K L I F Y F Q M N S E Q
Patient 5 (0) FM877565 M K D N K L I F Y F Q M N S E C
Patient 6
0 AM408180 M K D N K L I F Y F Q M N S E Q
174 AM408181 M K D N K L I F Y F Q M N S E Q
Patient 7
0 FM877566 M K D N K L I F Y F Q M N S E Q
504 FM877567 M K D N K L I F Y F Q M N S E Q
Patient 8 (0) AM408182 M K D N K L I F Y F Q M N S E Q
Patient 9
0 FM877568 M K D N K L I F Y F Q M N S E Q
816 FM877569 M K D N K L I F Y F Q M N S E Q
Patient 11
0 FM877570 M K D N K L I F Y F Q M N S E Q
775 FM877571 M K D N K L I F Y F Q V N S E Q
945 FM877572 M K D N K L I F Y F Q V N S E Q
Patient 12
0 AM408183 M K D N K L I F Y F Q M N S E Q
107 AM408184 M K D N K L I F Y F Q M N S E Q
a Given as wild-type (WT) HIV-1 or HIV-2 or as the patient number and the length of therapy (in days).
b Underlined boldface letters represent emerging drug resistance mutations. Boldface letters that are not underlined represent HIV-1 drug resistance mutations
found as natural polymorphisms in our samples. Underlined lightface letters represent HIV-2 polymorphisms that could affect drug susceptibility.
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During natural HIV infection, the virus is under pressure from
the immune system, and in the case of dual infection, compe-
tition between the two viruses might increase the pressure on
each of the viruses. When effective treatment is used, viruses
have only a small window of opportunity to acquire resistance
during periods of suboptimal drug levels, unless the mutant
virus is already archived. Therefore, the reduced pressure on
the singly infecting virus (monoinfection) might enable it to
acquire resistance more easily than the viruses in a dually
infected patient.
The presence of several HIV-1 PI mutations as natural poly-
morphisms in HIV-2 has resulted in reduced susceptibility to
some PIs (42, 49). A recent study of the activities of currently
approved PIs against the HIV-2 protease has shown that lopi-
navir, saquinavir, tipranavir, and darunavir exhibit the highest
potencies (in that order) and that atazanavir, nelfinavir, and
amprenavir show the lowest potencies (in that order) (7). Se-
quence analysis of the protease region during this study has
revealed the natural presence of nine minor HIV-1 PI muta-
tions, L10V, G16E, K20R, L33V, M36I, I62V, A71V, G73A,
and I93L, and three major mutations, V32I, M46I, and I47V,
which may explain the reduced susceptibility of wild-type
HIV-2 strains to several PIs (26).
Drug resistance mutations are selected less frequently in
patients taking a ritonavir-boosted PI than in those taking a
nonboosted PI. However, it has been reported that while the
same mutations usually emerge with boosted and nonboosted
PIs, the relative frequency of mutations may differ (26), and
that an accumulation of several mutations is often necessary to
cause significant resistance to boosted PIs (26). In HIV-1,
LPV/r resistance is usually associated with the accumulation of
specific resistance mutations in the HIV-1 protease gene
(L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P,
A71I/L/T/V, V82A/F/T, I84V, and L90M) (31, 37); however,
resistance is rare in patients whose first PI is LPV/r, with some
exceptions (26). A few specific mutations, most notably I47A
and V32I, are associated with high-level resistance to LPV/r
even for patients whose first PI is LPV/r (15, 28, 39). A recent
report on the phenotypic susceptibility of HIV-2 to LPV/r has
shown that the presence of the V47A mutation resulted in a
substantial reduction in susceptibility to lopinavir (38). In our
study, the protease sequences, after viral rebound, showed the
V47A (patients 2 and 11), V33I (patient 11), and F53V (pa-
tient 2) mutations emerging as a result of LPV/r pressure in a
background where the L10V, K20R, V32I, L33V, M36I, M46I,
I62V, A71V, G73A, and I93L mutations were present as
natural polymorphisms. Therefore, the virological failure
observed for patients 2 and 11 could be attributed partly to
high-level drug resistance to LPV/r.
Analysis of the RT sequences in patients with viral rebound
revealed first the M184I (patient 2) and later the M184V
(patients 2 and 11) mutation emerging due to drug pressure.
These mutations are associated with 1,000-fold phenotypic re-
sistance to 3TC (24, 27). The Q151M mutation, frequently
found in HIV-2 patients failing an NRTI-containing regimen
(42), was absent in these patients. Apart from the ZDV-asso-
ciated secondary mutations V75I and K219Q/E, present as
natural polymorphisms, other ZDV mutations have not been
found in any of the patients. As previously observed, accumu-
lation of the six thymidine analogue resistance mutations,
M41L, D67N, K70R, L210W, T215Y, and K219Q/E (32),
marking classic ZDV resistance in HIV-1 (1, 6, 9, 23, 49), was
also absent in the HIV-2 sequences. Therefore, we conclude
that high-level resistance to 3TC also contributed to the viro-
logical failure observed for patients 2 and 11 and that the
viruses in these patients either are sensitive to ZDV or have as
yet unidentified ZDV-associated mutations.
The presence of these high-level PI and RT inhibitor resis-
tance mutations in patient 2 (after 5 months on HAART) and
patient 11 explains the observed virological failures. Although
it has been reported that drug resistance is rare in patients
taking LPV/r as part of the first-line therapy (15, 28, 39), the
presence of background mutations may shorten the time to
development of resistance in HIV-2 relative to that for HIV-1
(43), as observed in this study. In HIV-1, the emergence of the
LPV/r mutation I47A is a two-step process, going from I to V
to A, while in HIV-2, it occurs in a single step from V to A,
making the emergence of this mutation easier and faster in
HIV-2 (38). However, HIV-2 V47A mutants were found to
retain susceptibility to other PIs and seemed to be hypersus-
ceptible to atazanavir and saquinavir (38). This finding makes
these drugs useful as second-line PIs for our HIV-2 patients,
especially saquinavir, which has been reported to have potent
activity against HIV-2 (7).
Generally, fewer mutations accumulated in these HIV-2 pa-
tients with viral rebound than in those from previous studies (1,
6, 9, 23), and the Q151M mutation was absent. This finding
indicates that efficient therapy results in fewer mutations and
therefore less cross-resistance to other drugs. This allows the
viruses to retain susceptibility to other drugs that can be used
in subsequent treatment regimens.
Analysis of sequences from other patients with viral rebound
did not indicate the presence of known drug resistance muta-
tions. However, in subsequent samples, the viral load either
returned to undetectable levels or was substantially reduced,
indicating that the rebound was in fact only a viral blip (a
temporarily elevated viral load) or a consequence of poor
adherence.
We report the response of 20 HIV-2-infected and dually
infected patients to a HAART regimen and the finding that the
combination of ZDV, 3TC, and LPV/r is effective at achieving
efficient and durable viral suppression in both HIV-2-infected
and dually infected patients. After more than 3 years, only
three patients need second-line therapy, one due to adverse
reactions to LPV/r and two due to high-level resistance to
LPV/r and 3TC. New potential drug resistance mutations, not
previously observed in HIV-1, were observed in this study.
These mutations could be primary determinants of drug resis-
tance in HIV-2, so there is a need to develop phenotypic
resistance assays for HIV-2 to determine their clinical rele-
vance. In conclusion, the response of HIV-2 to HAART can be
similar to that of HIV-1, provided that an optimal drug regi-
men is chosen. This further highlights the importance of choos-
ing PIs and RT inhibitors that are active against HIV-2.
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